MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

Last updated: November 4, 2024
Sponsor: Masonic Cancer Center, University of Minnesota
Overall Status: Active - Recruiting

Phase

2

Condition

Neurologic Disorders

Multiple Sclerosis

Bone Marrow Disorder

Treatment

cALD SR-B (Standard-Risk, Regimen B)

IMD Preparative Regimen

cALD SR-A (Standard-Risk, Regimen A)

Clinical Study ID

NCT02171104
2013LS104
  • Ages < 55
  • All Genders

Study Summary

This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 0 through 55 years of age

  • Adequate graft available

  • Adequate organ function

  • Eligible Diseases:

  • Mucopolysaccharidosis Disorders:

  • MPS IH (Hurler syndrome)

  • MPS II (Hunter syndrome) if the patient has no or minimal evidence ofsymptomatic neurologic disease but is expected to have a neurologicphenotype

  • MPS VI (Maroteaux-Lamy syndrome)

  • MPS VII (Sly syndrome)

  • Glycoprotein Metabolic Disorders:

  • Alpha mannosidosis

  • Fucosidosis

  • Aspartylglucosaminuria

  • Sphingolipidoses and Recessive Leukodystrophies:

  • Globoid cell leukodystrophy

  • Metachromatic leukodystrophy

  • Niemann-Pick B patients (sphingomyelin deficiency)

  • Niemann-Pick C subtype 2

  • Peroxisomal Disorders:

  • Adrenoleukodystrophy with cerebral involvement

  • Zellweger syndrome

  • Neonatal Adrenoleukodystrophy

  • Infantile Refsum disease

  • Acyl-CoA-Oxidase Deficiency

  • D-Bifunctional enzyme deficiency

  • Multifunctional enzyme deficiency

  • Alpha-methylacyl-CoA Racmase Deficiency (AMACRD)

  • Mitochondrial Neurogastrointestingal Encephalopathy (MNGIE)

  • Severe Osteopetrosis (OP)

  • Hereditary Leukoencephalopathy with axonal spheroids (HDLS; CSF1R mutation)

  • Other Inherited Metabolic Disorders (IMD): Patients will also be considered whohave other life-threatening, rare lysosomal, peroxisomal or other similarinherited disorders characterized by white matter disease or other neurologicmanifestations for which there is rationale that transplantation would be ofbenefit, such as certain patients with Wolman's disease, GM1 gangliosidosis,I-cell disease, Tay-Sachs disease, Sandhoff disease or others.

  • Voluntary written consent

Exclusion

Exclusion Criteria:

  • Pregnancy - menstruating females must have a negative serum or urine pregnancy testwithin 14 days of study treatment start

  • Prior myeloablative chemotherapy exposure within 4 months of the start ofconditioning on this protocol (patients excluded for this reason may be eligible forother institutional protocols)

  • Uncontrolled bacterial, fungal or viral infections including HIV (including activeinfection with Aspergillus or other mold within 30 days)

Study Design

Total Participants: 100
Treatment Group(s): 8
Primary Treatment: cALD SR-B (Standard-Risk, Regimen B)
Phase: 2
Study Start date:
July 10, 2014
Estimated Completion Date:
July 14, 2028

Connect with a study center

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota 55455
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.